论文部分内容阅读
目的:观察吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌的治疗效果。方法:选取经手术或病理学证实的胰腺癌患者73例。随机分成实验组(38例)用吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌4周,对照组(35例)用顺铂联合卡莫氟治疗晚期胰腺癌4周,比较两组的治疗效果和不良反应。结果:对照组部分缓解率为20.0%,半年生存率为57.1%,无1年以上生存者,疼痛改善率为40.0%;实验组部分缓解率为31.6%,半年及一年生存率分别为57.9%和26.3%,疼痛改善率为63.2%,两组比较均有统计学差异(P<0.05)。两组均有不同程度的骨髓抑制和胃肠道反应,其中骨髓抑制具有统计学差异(P<0.05)。结论:吉西他滨联合顺铂、卡莫氟治疗晚期胰腺癌患者可有效延长患者生命,改善生活质量,并无严重的不良反应。
Objective: To observe the effect of gemcitabine plus cisplatin and carmofurin in the treatment of advanced pancreatic cancer. Methods: 73 cases of pancreatic cancer confirmed by surgery or pathology were selected. Randomly divided into experimental group (n = 38), gemcitabine plus cisplatin and carmofurin for advanced pancreatic cancer for 4 weeks, and control group (n = 35) for cisplatin combined with carmofurin for advanced pancreatic cancer for 4 weeks. The therapeutic effect was compared between the two groups And adverse reactions. Results: In the control group, the partial remission rate was 20.0%, the half-year survival rate was 57.1%, and those who did not have more than one year’s survival rate were 40.0%. The partial remission rate in the experimental group was 31.6%, and the half-year and one-year survival rates were 57.9 % And 26.3% respectively. The improvement rate of pain was 63.2%. There was significant difference between the two groups (P <0.05). Both groups had different degrees of myelosuppression and gastrointestinal reactions, bone marrow suppression was statistically significant (P <0.05). Conclusion: Gemcitabine combined with cisplatin and carmofurin in patients with advanced pancreatic cancer can effectively prolong the life of patients and improve the quality of life without serious adverse reactions.